Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influvac Immunogenicity and Safety for Southern Hemisphere 2015
NCT02381418Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Mar 2015
- Primary completion
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inactivated influenza vaccine (surface antigen) in influenza, sponsored by Abbott Laboratories. Primary endpoint: Serum Antihemagglutinin Antibody Titers and Derived Parameters at 3 weeks. Started Mar 2015; status: completed.
02
Drugs
inactivated influenza vaccine (surface antigen)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02381418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381418.